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Kaposi’s sarcoma-associated herpesvirus (KSHV) RTA transcription factor is recruited to its responsive
elements through interaction with a Notch-mediated transcription factor, RBP-J, indicating that RTA mimics
cellular Notch signal transduction to activate viral lytic gene expression. To test whether cellular Notch signal
transduction and RTA are functionally exchangeable for viral gene expression, human Notch intracellular
(hNIC) domain that constitutively activates RBP-J transcription factor activity was expressed in KSHV-
infected primary effusion lymphoma BCBL1 cells (TRExBCBL1-hNIC) in a tetracycline-inducible manner.
Gene expression profiling showed that like RTA, hNIC robustly induced expression of a number of viral genes,
including viral interleukin 6 (vIL-6), K3, and K5. Unlike RTA, however, hNIC was not capable of evoking the
full repertoire of lytic viral gene expression and thereby lytic replication. To further understand the role of
Notch signal transduction in KSHV gene expression, vIL-6 growth factor and K5 immune modulator genes
were selected for detailed analysis. Despite the presence of multiple RBP-J binding sites, hNIC targeted the
specific RBP-J binding sites of vIL-6 and K5 promoter regions to regulate their gene expression. These results
indicate that cellular Notch signal transduction not only is partially exchangeable with RTA in regard to
activation of viral lytic gene expression but also provides a novel expression profile of KSHV growth and
immune deregulatory genes that is likely different from that of RTA-independent standard latency program as
well as RTA-dependent lytic reproduction program.
Kaposi’s sarcoma-associated herpesvirus (KSHV), also
called human herpesvirus 8, is thought to be an etiologic agent
of Kaposi’s sarcoma (KS) (8). KSHV is also associated with
two diseases of B-cell origin: primary effusion lymphoma and
an immunoblast variant of Castleman disease (2, 5). An im-
portant step in the herpesvirus life cycle is the switch from
latency to lytic replication. The KSHV replication and tran-
scription activator (RTA) plays a central role in this switch.
Ectopic expression of KSHV RTA is sufficient to disrupt viral
latency and activate lytic replication to completion (22, 43, 57,
60). RTA activates the expression of numerous viral genes in
the KSHV lytic cycle, including its own promoter, polyadenyl-
ated nuclear RNA, K12, ORF57, vOX-2, K14/vGPCR (viral
G-protein-coupled receptor), and vIRF1. While the details of
RTA-mediated transcriptional activation remain unclear, sev-
eral pieces of evidence suggest that RTA activates its target
promoter through direct binding to the specific sequence (40)
and/or interaction with various cellular transcriptional factors.
In fact, numerous cellular proteins, such as Stat3, KRBP, RBP-
J/CBF1, and CBP, interact with RTA, and these interactions
synergize RTA transcriptional activity (24, 25, 37, 55, 64).
Furthermore, our recent study demonstrated that RTA re-
cruits cellular SWI/SNF and TRAP/Mediator complexes
through its carboxy-terminal short acidic sequence. Recruit-
ment of these complexes onto viral lytic promoters is essential
for their effects on target promoters and thus for KSHV reac-
tivation (23).
Epstein-Barr virus (EBV) EBNA2 and KSHV RTA have
been shown to be recruited to their responsive elements
through interaction with the transcription factor RBP-J (29,
37, 41). RBP-J binding sites are present in a number of
EBNA2- and RTA-regulated viral promoters. RBP-J, which
was originally purified and characterized by Kawaichi et al.
(34) and Hamaguchi et al. (26), is highly conserved in evolution
from nematodes to humans. Biochemical and genetic studies
have demonstrated that RBP-J acts downstream of the re-
ceptor Notch. Activation of the Notch receptor by binding of
its ligands (Delta, Jagged, or Serrate) leads to proteolytic
cleavage of the receptor at the inner side of the membrane
(52). The Notch intracellular domain (NIC) is then translo-
cated to the nucleus, where it activates genes by interacting
with RBP-J. EBNA2 and RTA may thus be regarded as
functional homologs or mimickers of the activated Notch pro-
tein. Indeed, NIC has been shown to be capable of functionally
replacing EBNA2 in the context of EBV for primary B-cell
transformation (21, 66). However, the cellular targets of cel-
lular NIC do not completely overlap with those of EBNA2:
both activate CD21 gene expression and repress immunoglob-
ulin  (Ig) expression, whereas EBNA2, but not NIC, acti-
vates CD23a gene expression (59). Like EBV EBNA2, KSHV
RTA strongly induces CD21 and CD23a expression through
RBP-J binding sites in the first intron of CD21 and in the
CD23a core promoter, respectively (7). However, unlike EBV
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EBNA2, which alters Ig and c-myc gene expression, RTA
does not affect Ig and c-myc expression, indicating that
KSHV RTA targets the Notch signal transduction pathway in
similar but distinct ways from those of EBV EBNA2. Further-
more, RBP-J has been shown to be a critical component in
mediating RTA activation of several KSHV target genes, in-
cluding those for ORF57, thymidine kinase, and K14/vGPCR
(37, 39). In fact, RBP-J plays an essential role in RTA-me-
diated lytic reactivation of KSHV, since such reactivation is
completely defective in RBP-J/ cells while being efficient in
RBP-J/ cells (38). This indicates that RBP-J plays an
important role in the RTA-mediated lytic gene expression by
directing RTA to viral target promoters through interaction.
The great puzzle of KSHV pathogenesis is that certain viral
lytic genes either behave as oncogenes or at least have growth-
promoting antiapoptotic or angiogenic properties (27). How-
ever, either these activities may be alleviated during the lytic
replication cycle because cell growth is blocked by RTA-in-
duced lytic replication. On the other hand, it is possible that
cellular signal transduction, for example, the Notch signal
pathway, may induce a unique expression profile of KSHV
growth and immune deregulatory genes that is distinct from
that of the latency program as well as the lytic program. In fact,
the regulation of K14/vGPCR transcripts by RBP-J suggests
the possibility that Notch signaling is able to induce expression
of this RNA outside the context of lytic KSHV replication (37,
39). Furthermore, this unique viral expression profile may ul-
timately lead to a favorable environment for viral persistent
infection and pathogenesis. To test this hypothesis, we con-
structed KSHV-infected primary effusion lymphoma BCBL1
cells (TRExBCBL1-hNIC) expressing the constitutively active
form of the human Notch intracellular (hNIC) domain in a
tetracycline-inducible manner. It showed that hNIC specifically
induced the expression of a number of KSHV genes, including
K3, K5, and viral interleukin 6 (vIL-6). Particularly, hNIC-
mediated activation of K5 gene expression conferred the
downregulation of major histocompatibility complex class I
(MHC-I) and CD54 surface expression. These results demon-
strate that cellular hNIC induces the expression of a selected
subset of KSHV genes, in particular growth and immune de-
regulatory genes, independently of RTA. Thus, as seen with
EBV EBNA2, cellular Notch signal transduction is partially
exchangeable with RTA in regard to activation of viral lytic
gene expression but also provides a novel RTA-independent
viral gene expression profile.
MATERIALS AND METHODS
Cell culture and transfection. 293T, BJAB, and BCBL-1 cells were grown in
Dulbecco’s modified Eagle’s medium or RPMI 1640 medium supplemented with
10% fetal calf serum. OT11 (RBP-J/) and OT13 (RBP-J/) cells (kindly
provided by T. Honjo, Kyoto University) were grown in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal calf serum and 100 U/ml mouse
gamma interferon.
Luciferase assay. Cells were transfected with pvIL6-Luc (kindly provided by
Ren Sun, University of California, Los Angeles) or pK5-Luc, and -galactosidase
plasmid, and the indicated amount of empty vector or hNIC expression vector
(kindly provided by P. Ling, Baylor College of Medicine) (21). At 48 h post-
transfection, cells were washed twice with phosphate-buffered saline, lysed, and
analyzed by luciferase assay (Promega, Madison, WI). Luciferase levels were
normalized to -galactosidase activity and presented as the increase in induction
compared with the control.
Flow cytometry. Cells (5  105) were washed with RPMI 1640 medium con-
taining 10% fetal calf serum and incubated for 30 min with antibodies. Cells were
then incubated for 20 min at 4°C with secondary anti-mouse antibodies (Pharm-
ingen, San Diego, CA). After each sample was washed, it was fixed with 2%
paraformaldehyde, and fluorescence-activated cell sorting analysis was per-
formed with a FACScan (Becton Dickinson, Mountainview, CA).
Real-time QPCR for KSHV. RNA was isolated as previously described (7)
using RNAzol (Tel-Test, Inc., Friendswood, Texas). Poly(A) mRNA was pre-
pared using dT beads (QIAGEN Inc., Valencia, CA) and reverse transcribed
using Superscript II reverse transcriptase (Life Technologies, Rockville, MD)
according to the manufacturer’s recommendations. The procedures for real-time
quantitative PCR (QPCR) analysis have been previously described (49, 58). The
KSHV primers used in this analysis are available upon request from the authors.
The final PCR contained 2.5 l primer mix (final concentration, 166 nM), 7.5 l
2 SYBR PCR mix (Applied Biosystems, Foster City, CA), and 5 l sample. To
guard against contamination and handling errors, all real-time QPCR mixtures
were assembled in a segregated clean room using filtered pipette tips and a robot.
Real-time PCR was performed using an ABI PRIZM 5700 machine (Applied
Biosystems, Foster City, CA) and universal cycle conditions.
CHIP assay. Chromatin immunoprecipitation (CHIP) assay was performed
according to the manufacturer’s instructions (Upstate Biotech) with several
modifications. Briefly, culture dishes were treated with 1% formaldehyde for 10
min at room temperature. After a brief sonication, immunoprecipitation was
performed using the appropriate antibody. After several washings, the immuno-
complexes were eluted with 50 mM Tris, pH 8.0, 1 mM EDTA, and 1% sodium
dodecyl sulfate at 65°C for 10 min, adjusted to 200 mM NaCl, and incubated at
65°C for 5 h to reverse the cross-links. After successive treatments with 10 g/ml
RNase A and 20 g/ml proteinase K, the samples were extracted with phenol-
chloroform and precipitated with ethanol. One-tenth of the immunoprecipitated
DNAs was analyzed by PCR with the primer sets for R1 (5 primer, GGTAAG
CATATAAGGAACTCGGCG; 3 primer, AGCTATTAGGCGTGTACGACA
CGA), R2/3 (5 primer, TAATAGCTGCTGCTACGGGTTCCA; 3 primer,
TTGGGCCGCAGTGATATCTTCAAC), R4 (5 primer, AACTGCTCGAGG
CGACAACGCCAT; 3 primer, GGACACGCGTCATCACTAGTTATG), R5
(5 primer, CCCTTATTTCATAGGTCCGGTGTG; 3 primer, ACAACCCAC
CCTGCTTTAGCTCTA), and R6 (5 primer, GACAGTTTTCCAGGGAAAG
CCTGG; 3 primer, TGCAGCTGGGGTGGAAGTCTGAAA). Amplifications
(26 cycles) were performed with an MJ thermal cycler, and the PCR products
were analyzed in 3% polyacrylamide gels.
RESULTS
Tetracycline-inducible expression of hNIC in BJAB and
BCBL1 cells. To test whether Notch signaling affected KSHV
gene expression, the intracellular cytoplasmic region of human
Notch receptor (hNIC), which induces the constitutive activa-
tion of RBP-J-mediated transcription (42), was expressed in
KSHV-infected BCBL1 cells in a tetracycline-inducible man-
ner as previously described (47). These cells were designated
TRExBCBL1-hNIC. KSHV-negative BJAB cells (TRExBJAB-
hNIC) expressing hNIC in a tetracycline-inducible manner
were also constructed as controls. Immunoblot assay showed
that treatment of these cells with doxycycline (doxy) rapidly
induced hNIC expression (Fig. 1A). As previously shown (7),
RTA also effectively induced the upregulation of CD21 and
CD23 surface expression and downregulation of MHC-I and
CD54 surface expression on BCBL1 cells (7, 62) (Fig. 1B). To
examine the effect of hNIC on lymphocyte antigen expression,
TRExBCBL1-cDNA5 control cells and TRExBCBL1-hNIC
cells were tested for CD21, CD23, MHC-I, and MHC-II sur-
face expression upon doxy treatment for 0, 24, and 48 h. It
showed that hNIC considerably downregulated MHC-I surface
expression on TRExBCBL-1 cells, whereas it did not affect
CD21, CD23, and MHC-II surface expression (Fig. 1B and
data not shown). In contrast, hNIC expression has been shown
to have no effect on MHC-I surface expression on TRExBJAB-
hNIC cells (7). This indicates that hNIC specifically downregu-
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lates MHC-I surface expression on KSHV-infected BCBL1
cells, but not on uninfected BJAB cells.
Induction of K3 and K5 expression by hNIC. Tetracycline-
inducible expression of KSHV RTA in BCBL1 cells induces
K3 and K5 expression, which leads to the drastic downregula-
tion of MHC-I and CD54 surface expression (7). Because of
their functional similarity, we compared the effect of hNIC on
lymphocyte surface antigen expression with that of RTA.
TRExBCBL1-cDNA5, TRExBCBL1-hNIC, and TRExBCBL1-
RTA cells were treated with doxy for 0, 24, 48, and 72 h and
tested for expression of various surface antigens, including
MHC-I, MHC-II, and CD54. KSHV K8.1 envelope protein
was also included as a means to determine lytic replication. It
showed that hNIC expression induced the strong downregula-
tion of MHC-I and CD54 on TRExBCBL1 cells at levels equiv-
alent to those induced by RTA expression (Fig. 2). However,
unlike TRExBCBL1-RTA cells on which the surface expres-
sion of K8.1 viral envelope protein increased upon RTA ex-
pression, TRExBCBL1-hNIC cells displayed no detectable in-
crease of K8.1 surface expression upon hNIC expression (Fig.
2). Since KSHV K3 and K5 efficiently downregulated MHC-I
and CD54 surface expression (11, 12, 31, 32, 50), we tested
whether hNIC affected viral protein expression, specifically K3
and K5. Immunoblotting assay with various KSHV antibodies
showed that hNIC induced K3, K5, and vIL-6 protein levels but
not K8.1 and LANA protein levels (Fig. 3). These results
FIG. 1. Induction of hNIC expression and MHC-I downregulation. (A) Induction of hNIC expression. TRExBJAB-cDNA5, TRExBJAB-hNIC,
TRExBCBL1-cDNA5, and TRExBCBL1-hNIC cells were stimulated with or without 1 g/ml doxy for 0, 24, 48 or 72 h. Whole-cell lysates were
used for immunoblotting with anti-Flag (NIC) and antitubulin (Tubulin) antibodies. (B) Downregulation of MHC-I surface expression.
TRExBCBL1-cDNA5 (black lines), TRExBCBL1-hNIC (red lines), and TRExBCBL1-RTA (blue lines) cells were treated with 1 g/ml doxy for
0, 24, and 48 h, fixed, and then reacted with the indicated antibodies for flow cytometry.
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showed that hNIC efficiently induced K3, K5, and vIL-6 ex-
pression independently of RTA, which likely led to downregu-
lation of MHC-I and CD54 surface expression. However, un-
like RTA that efficiently induced K8.1 envelope expression,
hNIC did not affect K8.1 envelope protein expression under
the same conditions (Fig. 2 and 3).
Genome-wide effects of hNIC on KSHV gene expression. In
order to evaluate the impact of hNIC on the KSHV life cycle,
we analyzed whether hNIC expression affected KSHV gene
expression in latently infected BCBL-1 cells. Approximately 1
 107 TRExBCBL1-cDNA5 cells and TRExBCBL1-hNIC
cells were treated with doxy for 0, 24, and 48 h, and mRNAs
were isolated, reverse transcribed, and analyzed using our pre-
viously developed real-time quantitative reverse transcription-
PCR array for KSHV (17, 20). Hierarchical clustering was
performed with KSHV genes only, not on the samples, which
were a time series. Clustering was based on a standard corre-
lation metric. A detailed validation of these methods of anal-
ysis for viral arrays has been published recently (18). Figure 4
shows the tree view representation after hierarchical clustering
of glyceraldehyde-3-phosphate dehydrogenase-normalized rel-
ative expression levels (dCT) of KSHV viral mRNAs. It
showed that hNIC expression efficiently induced expression of
a subset of KSHV genes, including vIL-6, K3, K4, K5, K7,
PAN, Orf4, Orf11, Orf17, Orf23, Orf32, Orf35, Orf37, Orf38,
Orf39, Orf46, Orf48, Orf49, Orf52, Orf53, Orf55, Orf57,
Orf66, Orf70, and Orf75 (Fig. 4). Particularly, the induction
kinetics of K5, K7, and Orf11 mRNAs were faster than those
of other viral genes upon doxy treatment (Fig. 4). In addition,
the low levels of K5, Orf11, and K7 were also detected in
FIG. 2. MHC-I and CD54 surface expression. TRExBCBL1-cDNA5, TRExBCBL1-hNIC, and TRExBCBL1-RTA cells were treated with 1
g/ml doxy for 0, 24, 48 h, and 72 h, fixed, and then reacted with antibodies indicated to the left of the figure for flow cytometry. Gray lines indicate
control TRExBCBL1-cDNA5 cells, red lines indicate TRExBCBL1-hNIC cells, and blue lines indicate TRExBCBL1-RTA cells.
FIG. 3. Induction of K3, K5, and vIL-6 expression by hNIC.
TRExBCBL1-cDNA5 (Vector), TRExBCBL1-hNIC (hNIC), and
TRExBCBL1-RTA (RTA) cells were treated with 1 g/ml doxy for 0
and 48 h. Whole-cell lysates were used for immunoblotting with anti-
bodies specific for K3, K5, vIL-6, K8.1, and LANA as indicated to the
left of the figure. These results were reproduced on at least two inde-
pendent occasions.
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TRExBCBL1-NIC cell expression before doxy treatment,
which was likely derived from the leakiness of tetracycline-
inducible NIC expression (Fig. 4). These results showed that
Notch signaling induced expression of a selected subset of
KSHV genes. However, unlike RTA, hNIC was not capable of
evoking the full repertoire of lytic viral gene expression and
thereby lytic replication.
Increase of vIL-6 promoter activity by hNIC. Notch signal
transduction has been shown to modulate cellular growth fac-
tor expression, which regulates growth control and differenti-
ation (42, 44, 53). In order to delineate the effect of Notch-
mediated activation on KSHV gene expression and pathogenesis,
the vIL-6 gene promoter was selected for further analysis. The
previous study has defined the RTA-responsive element to the
48-bp region spanning between 462 and 414 from the vIL-6
translational initiation site (14). The upstream sequence of the
vIL-6 promoter region was cloned into pGL3-basic to derive
luciferase reporter pvIL-6(507) plasmid (the numbers in pa-
rentheses indicate the lengths of the upstream region from the
vIL-6 translation initiation site). Reporter plasmids were trans-
fected into BJAB B cells and 293T epithelial cells together with
either pcDNA5/hNIC or vector pcDNA5. Plasmid pGK-Gal
that contains the coding sequence for -galactosidase under
the control of a constitutively active promoter was included as
an internal control for transfection efficiency. Cell extracts
were harvested and assayed for both luciferase and -galacto-
sidase activities at 48 h posttransfection. It showed that pvIL-
6(507) was activated 22- and 16-fold by hNIC expression in
BJAB and 293T cells, respectively, indicating that the 507-
nucleotide sequence upstream of the vIL-6 open reading frame
is sufficient to respond to hNIC-mediated activation (Fig. 5).
Precise inspection reveals that the vIL-6 promoter region con-
tains two potential RBP-J binding sites (GTGGGAA), R1
(GCGGGAA) and R2 (GTGGGGA) (Fig. 5). To further iden-
tify the specific sequence of the vIL-6 promoter responsible for
hNIC-mediated activation, we generated additional luciferase
reporter constructs containing deletions and/or point muta-
tions (Fig. 5). These reporter plasmids were cotransfected with
pcDNA5/hNIC or pcDNA5 into BJAB or 293T cells as de-
scribed above. As shown in Fig. 5, when the sequence between
507 and 412 was deleted, the reporter response to hNIC
was affected at a minimal level. However, when the sequence
between 507 and 336 was deleted, the reporter response to
hNIC was drastically reduced (Fig. 5). Furthermore, luciferase
assays with pvIL-6(-m507R1), pvIL-6(-m507R2), pvIL-6(-
m507R1/2), and pvIL-6(-m412) point mutants showed that mu-
FIG. 4. Genome-wide effects of hNIC on KSHV gene expression.
“Heat map” representation of KSHV mRNA upon hNIC expression
was determined by real-time quantitative reverse transcription-PCR.
The values were normalized to glyceraldehyde-3-phosphate dehydro-
genase mRNA levels, and the medians were centered. They were
clustered on the basis of a Euclidean metric and were represented on
a logarithm 2 scale, to allow for a more robust statistical analysis. Black
represents the decreased level and red represents the increased level
relative to the median (blue) across all time points for both conditions
(n 	 8). Vector-expressing BCBL1 cells (Vector) and hNIC-expressing
BCBL1 cells (hNIC) were examined. Arrows indicate KSHV K3, K5,
and vIL-6 (K2) genes.
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tation at the R2 site significantly abrogated the hNIC-mediated
activation of vIL-6 promoter activity (Fig. 5). These results
indicate that the R2 RBP-J binding site of vIL-6 promoter is
primarily responsible for hNIC-mediated activation.
We next asked whether RBP-J was necessary for the hNIC-
mediated activation of vIL-6 promoter activity. RBP-J/
knockout (OT11) and its revertant RBP-J/ (OT13) mouse
embryonic fibroblast (MEFs) were transfected with various
luciferase constructs containing the wild-type or mutant se-
quence of the vIL-6 promoter region together with pcDNA5/
hNIC or pcDNA5. This showed a near-total loss of the hNIC-
mediated activation of vIL-6 promoter activity in RBP-J/
OT11 cells (Fig. 6). In contrast, pvIL-6(507), pvIL-6(472),
and pvIL-6(412) promoter constructs that contained the R2
RBP-J site remained active upon hNIC expression in RBP-
J/ OT13 cells, whereas the pvIL-6(-m412) mutant con-
struct with the R2 site deleted showed no activation under the
same conditions (Fig. 6). Finally, RBP-J dominant-negative
mutant that contained a defect in DNA binding ability (61) was
transfected into 293T cells together with hNIC and vIL-6 pro-
moter constructs. This showed that the introduction of the
RBP-J dominant-negative mutant dramatically suppressed
the hNIC-mediated activation of vIL-6 promoter activity (Fig.
6, bottom). These results demonstrate that the hNIC-mediated
activation of vIL-6 promoter activity requires a functionally
active RBP-J factor and that the R2 RBP-J binding se-
quence of the vIL-6 promoter region likely plays an important
role in hNIC-mediated gene expression.
Increase of K5 promoter activity by hNIC. To further delin-
eate the effect of hNIC on K5 expression, we constructed
FIG. 5. Activation of vIL-6 expression induced by hNIC. (A) Schematic diagrams of the potential RBP-J binding sites within the vIL-6
promoter region. The positions of the two putative RBP-J binding sequences (R1 and R2), the mutations at the RBP-J binding sequences (mR1
and mR2), and the RTA-responsive elements (RRE) are shown. The numbers below the maps indicate the position relative to the translational
start site (1). The numbers to the right of the figure indicate the increase in induction in BJAB and 293T cells upon hNIC expression over the
control vector expression. (B) Luciferase assay. Wild-type (pGL3) or mutant vIL-6 promoter luciferase reporter together with the pGK--gal
construct was transfected into BJAB or 293T cells with pcDNA5 vector (Vector) or pDNA5-hNIC (hNIC). The mutant vIL-6 promoter luciferase
reporters used were pvIL-6(507), pvIL-6(472), pvIL-6(412), pvIL-6(-m507R1), pvIL-6(-m507R2), pvIL-6(-m507R1/2), and pvIL-6(-m412)
(only the last part of the plasmid designation is shown in the figure). At 48 h posttransfection, cell lysates were used for reporter assays. Luciferase
activity is presented as the average of three independent experiments.
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luciferase reporters containing the K5 promoter region. On the
basis of the presence of six potential RBP-J binding se-
quences within 1 kb of sequence upstream of the ATG codon
of the K5 gene, we constructed serial deletions from the 5
ends of the constructs [pK5(1042), pK5(952), pK5(781),
pK5(496), and pK5(232)] and examined their responses to
hNIC expression (Fig. 7A). In addition, pK5(-m781) contained
the replacement of R3 (AAGGGTC) and R4 (CTGGGAA)
sequences with mR3 (CCTTTGA) and mR4 (AGTTTCC) se-
quences, respectively, and both pK5(-m1042) and pK5(-m496)
contained the replacement of R5 (AACGCTT) sequence
with mR5 (CCATAGG) sequence (Fig. 7A). Interestingly,
pK5(496) promoter activity showed the maximum increase
(10.5-fold in 293T cells and 4.2-fold in BJAB cells) upon hNIC
expression over control vector expression, whereas other pK5
reporters showed significantly reduced levels of activation (1.5-
to 2.7-fold) under the same conditions (Fig. 7). Furthermore,
the pK5(-m781) construct that contained the mutations at the
R3 and R4 sequences remained active upon hNIC expression,
whereas the pK5(-m496) construct that contained the mutation
at the R5 sequence no longer responded to hNIC expression
(Fig. 7). Finally, pK5(m-1042) that contained all other RBP-J
binding sites with the mutated R5 showed no activation upon
NIC expression (Fig. 7). These results indicate that the R5
RBP-J binding sequence between 496 and 232 of the K5
promoter region is the primary target for hNIC action. Fur-
thermore, the K5 promoter sequence upstream of 496 bp
may contribute to the negative effect on K5 expression.
To further detail the activation of the K5 promoter induced
by hNIC, OT11 RBP-J/ and OT13 RBP-J/ MEFs were
transfected with various luciferase constructs containing the
wild-type or mutant sequence of the K5 promoter region to-
gether with pcDNA5/hNIC or pcDNA5. This revealed that as
seen with the vIL-6 promoter (Fig. 6), a near-total loss of the
hNIC-mediated activation of K5 promoter activity was ob-
served in OT11 RBP-J/ cells (Fig. 8A). In contrast,
pK5(496) promoter constructs showed a maximum level of
activation induced by hNIC in RBP-J/ OT13 cells, whereas
pK5(1042), pK5(781), and pK5(-m496) promoter con-
structs showed a minimal level of activation under the same
conditions (Fig. 8A). Finally, as seen with the vIL-6 promoter
(Fig. 6), introduction of RBP-J dominant-negative mutant
dramatically abrogated the hNIC-mediated activation of K5
promoter activity, in particular pK5(496) promoter activity
(Fig. 8B). These results demonstrate that the hNIC-mediated
activation of K5 promoter activity requires a functionally active
RBP-J and that the R5 RBP-J binding sequence of the K5
promoter region likely plays a major role in hNIC-mediated
activation.
To further confirm the primary role of the R5 RBP-J bind-
ing sequence in hNIC-mediated activation, chromatin immu-
noprecipitation assay was used to examine the amount of hNIC
protein recruited onto the RBP-J binding sequences of K5
promoters. 293T cells were transfected with pGL3 or
pK5(1042) reporter together with the Flag-tagged hNIC ex-
pression vector. Untransfected 293T cells were also included as
controls. At 48 h posttransfection, cell lysates were used for
immunoprecipitation with an anti-Flag antibody or without
antibody. Immune complexes were then used for PCR analysis
with primers specific for each RBP-J binding sequence. It
showed that the Flag-tagged hNIC was efficiently recruited
onto the R5 RBP-J binding sequence, whereas other RBP-J
binding sequences showed no detectable level of hNIC recruit-
ment (Fig. 8C). This indicates that the activation of K5 pro-
moter activity is most likely mediated by the efficient recruit-
ment of hNIC onto the R5 RBP-J binding sequence.
DISCUSSION
RBP-J is a downstream transcription factor of the Notch
pathway that is important in development and cell fate deter-
mination (44, 45, 53). The intracellular domain of activated
Notch receptor is released from the plasma membrane through
proteolytic cleavage and is translocated to the nucleus, where
FIG. 6. Role of RBP-J in the hNIC-mediated activation of vIL-6
promoter activity. (Top) hNIC-mediated activation of vIL-6 requires
RBP-J expression. RBP-J/ OT11 and RBP-J/ OT13 MEFs
were transfected with vIL-6 promoter luciferase reporters and pGK-
-gal together with pcDNA5 vector or pDNA5-hNIC. The mutant
vIL-6 promoter luciferase reporters used were pvIL-6(507), pvIL-
6(472), pvIL-6(412), and pvIL-6(-m412) (only the last part of the
plasmid designation is shown in the figure). At 48 h posttransfection,
cell lysates were used for reporter assays. Luciferase activity is pre-
sented as the average of three independent experiments. (Bottom)
Inhibition of the hNIC-induced activation of vIL-6 promoter activity by
RBP-J dominant-negative (DN) mutant. Wild-type (pGL3) or mu-
tant vIL-6 promoter luciferase reporter together with pGK--gal was
transfected into 293T cells with pDNA5-hNIC alone or with pcDNA5-
hNIC and pcDNA5-RBP-J DN vectors. At 48 h posttransfection, cell
lysates were used for reporter assays. Luciferase activity is presented as
the average of three independent experiments.
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it is directed to target promoters through RBP-J interaction
(42). A previous report (37) has shown that the KSHV RTA
protein mimics cellular Notch signal transduction by interact-
ing with RBP-J and by activating RBP-J-dependent activa-
tion of viral lytic gene expression. Here, we also demonstrate
that the constitutively active form of the human Notch signal-
ing molecule, hNIC, is partially exchangeable with RTA in
viral lytic gene expression. A microarray showed that hNIC
robustly induced expression of a number of viral genes, includ-
ing vIL-6, K3, and K5, but was not capable of evoking the full
repertoire of lytic viral gene expression. Further detailed anal-
ysis showed that hNIC targeted the specific RBP-J binding
sites of vIL-6 and K5 promoter regions to induce their gene
expression. These results indicate that cellular Notch signal
transduction not only is partially exchangeable with RTA in
regard to activation of viral lytic gene expression but also
provides a novel expression profile of KSHV growth and im-
mune deregulatory genes.
RTA transcription factor that controls the switch from la-
tency to lytic replication interacts with RBP-J to activate viral
gene expression. The fact that many KSHV lytic genes, includ-
ing RTA itself, contain RBP-J binding sites has raised the
possibility that RTA/RBP-J-mediated gene expression may
be central to the switch from latency to lytic replication (7, 37,
39). EBV EBNA2 has also been shown to be recruited to its
responsive elements through interaction with RBP-J (29, 37,
41), indicating that EBNA2 and RTA may thus be regarded as
functional homologs or mimickers of the activated Notch pro-
tein. Indeed, hNIC has been shown to be capable of function-
ally replacing EBNA2 in the context of EBV for primary B-cell
transformation (21). We also showed that hNIC was capable of
partially replacing the RTA function in KSHV gene expres-
FIG. 7. Activation of K5 expression induced by hNIC. (A) Schematic diagrams of the potential RBP-J binding sites within the K5 promoter
region. The six putative RBP-J binding (GTGG/AGAA) sequences (white R1 to R6 boxes) and mutants (hatched mR3 to mR5 boxes) are
indicated. Numbers indicate the position relative to the translational start site (1). The numbers to the right of the figure indicate the increase
in induction in BJAB and 293T cells upon hNIC expression over control vector expression. (B) Luciferase assay. Wild-type (pGL3) or mutant K5
promoter luciferase reporter together with pGK--gal construct was transfected into BJAB or 293T cells with pcDNA5 vector or pcDNA5-hNIC.
The mutant K5 promoter luciferase reporters used were pK5(1042), pK5(952), pK5(781), pK5(496), pK5(232), pK5(-m1042),
pK5(-m781), and pK5(-m496) (only the last part of the plasmid designation is shown in the figure). At 48 h posttransfection, cell lysates were used
for reporter assays. Luciferase activity is presented as the average of three independent experiments.
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sion. Interestingly, while hNIC induced the expression of ap-
proximately 24 KSHV genes and RTA contained the func-
tional RBP-J binding site in its promoter region, RTA was
not one of the genes induced by hNIC. A recent study has
demonstrated that RBP-J binding sites within the RTA pro-
moter are critical for the repression rather than the activation
of its expression (36). Specifically, LANA physically associates
with RBP-J, and this interaction represses RTA expression by
targeting this complex to the RBP-J binding sites within its
promoter, which ultimately leads to the maintenance of KSHV
latency (36). Thus, RBP-J binding sites in viral promoters
provide positive or negative effects on their gene expression,
which is likely dependent on the interaction with target tran-
scriptional factors. Nevertheless, these results indicate that
hNIC-mediated activation of KSHV gene expression is specific
and RTA independent.
Our previous report (7) demonstrated that KSHV RTA
induces both CD21 and CD23a surface expression on BJAB
cells, whereas cellular NIC induces only CD21 surface expres-
sion on BJAB cells. However, NIC expression was not capable
of inducing CD21 surface expression on KSHV-infected
BCBL1 cells. This is likely because the origin of primary effu-
sion lymphoma (PEL) cells is different from that of BJAB cells.
BAJB cells that are derived from mature B cells show the
surface expression of CD19, CD20, and CD21 mature B-cell
markers (56). In contrast, PEL cells that carry plasma cell types
do not express any of mature B-cell markers, including CD19,
CD20, and CD21 (6). Since NIC expression was not capable of
inducing CD21 surface expression on PEL cells, this indicates
that cellular transcription factors other than Notch-mediated
RBP-J activity are necessary for CD21 gene expression.
Despite the broad effect of hNIC on KSHV gene expression,
hNIC was not capable of inducing the complete cycle of viral
lytic replication, suggesting that a number of other cellular
partners are required for RTA to evoke the full repertoire of
lytic viral gene expression and thereby lytic replication. In fact,
Liang and Ganem (39) have also discussed as unpublished
results that ectopic expression of the Notch intracellular do-
main or EBNA2 fails to induce KSHV lytic replication. The
previous and current studies suggest that activation through
the RBP-J-mediated signal transduction is necessary for lytic
induction but not sufficient for the completion of lytic replica-
tion. Interestingly, K5 and Orf11 genes showed the faster ki-
netics of expression upon hNIC expression compared to the
FIG. 8. Role of RBP-J in the hNIC-mediated activation of K5
promoter activity. (A) hNIC-mediated activation of K5 requires
RBP-J expression. RBP-J/ OT11 and RBP-J/ OT13 MEFs
were transfected with K5 promoter luciferase reporters and pGK--gal
together with pcDNA5 vector or pDNA5-hNIC. The K5 promoter
luciferase reporters used pK5(1042), pK5(781), pK5(496),
pK5(232), and pK5(-m496) (only the last part of the plasmid desig-
nation is shown in the figure). At 48 h posttransfection, cell lysates
were used for reporter assays. Luciferase activity is presented as the
average of three independent experiments. (B) Inhibition of the hNIC-
induced activation of K5 promoter activity by RBP-J dominant-neg-
ative (DN) mutant. Wild-type (pGL3) or mutant K5 promoter lucif-
erase reporter together with pGK--gal was transfected into 293T cells
with pDNA5-hNIC alone or with pcDNA5-hNIC and pcDNA5-
RBP-J DN vectors. At 48 h posttransfection, cell lysates were used for
reporter assays. Luciferase activity is presented as the average of three
independent experiments. (C) CHIP assay. 293T cells were transfected
with pGL3 and pcDNA5-hNIC or pK5(1042) and pcDNA5-hNIC or
not transfected with DNA (No). At 48 h posttransfection, cell lysates
were used for immunoprecipitation with an anti-Flag antibody (Flag)
or without antibody (No Ab). Then, immune complexes were used for
PCR analysis with primers to specifically amply the R1, R2/3, R4, R5,
and R6 RBP-J binding sequences. PCR products were separated by
3% agarose gel electrophoresis.
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rest of other viral genes, suggesting that they may be the initial
targets for Notch signal transduction. Precise inspection re-
veals the potential six RBP-J binding sites in the K5 promoter
region. A series of mutational analysis indicated the complexity
of transcriptional regulation of the K5 promoter. First, the R5
RBP-J binding site within the K5 promoter likely played the
major role in the hNIC-mediated activation. CHIP assay of K5
promoter and reporter assay with RBJ-J dominant-negative
mutant further supported this notion. However, the deletion
mutations of the first four (R1, R2, R3, and R4) RBP-J sites
enhanced K5 promoter activity in both BJAB B cells and 293T
epithelial cells, indicating that they might influence K5 pro-
moter activity in a repressive way. These results were also
supported by the study of RBP-J-null murine fibroblasts.
RBP-J is a repressor in the ground state without upstream
signal transduction, whereas upon stimulation its interaction
with the Notch intracellular domain then relieves this repres-
sion and turns on target genes. This suggests that RBP-J may
initially target the first four R1, R2, R3, and R4 sites to repress
K5 promoter activity and to keep the ground status in the
absence of upstream Notch signaling. Upon stimulation, Notch
intracellular domain is then recruited to the R5 site through
RBP-J interaction to evoke K5 promoter activation. This
indicates that RBP-J is an important transcription factor that
regulates K5 gene expression in both positive and negative
ways.
Tomescu et al. (62) have described the surface downregula-
tion of MHC-I, CD31, and CD54 immunoregulatory proteins
by KSHV in newly infected endothelial cells. Analysis of viral
mRNA expression both in vivo within Kaposi’s sarcoma lesions
and in vitro in infected PEL and endothelial cells indicates that
KSHV gene expression is restricted to a small subset of latent
genes (3, 4, 9, 10, 15–17, 20, 33, 35, 46, 62, 65). While KSHV
lytic protein K3 and K5 are capable of downregulating MHC-I
and/or CD54, their contribution to immune evasion by KSHV
during latency is less clear. We showed that Notch signal trans-
duction induced K5 expression independent of RTA. This re-
sult may relate to the previous finding that K5 protein is de-
tected in KSHV latently infected KS lesion (48). It is possible
that K5 may be expressed at a low level in latently infected
cells, which is sufficient to induce surface molecule downregu-
lation. In addition, under this condition, K5 expression is likely
independent of the lytic transcription factor RTA but depen-
dent on the Notch signal-mediated RBP-J transcription fac-
tor. In fact, we found that KSHV-infected BCBL1 cells likely
displayed the constitutive activation of ligand-mediated Notch
signal transduction, evidenced by the expression of Jagged and
the complete proteolytic process of Notch receptors (unpub-
lished results). Furthermore, a recent report has shown that
KSHV-infected cells have elevated not only the level of acti-
vated Notch and but also the activated level of Notch-mediated
transcription activity (13). Furthermore, inhibitors that block
Notch activation resulted in apoptosis in primary and immor-
talized KS cells. The results suggest that targeting Notch sig-
naling may be of therapeutic value in KS patients.
RBP-J is a transcription factor whose function switches
from a repressor in the ground state to an activator upon
interaction with the Notch intracellular domain, which relieves
its repression activity and then gains its activation activity to
turn on target genes. Because of its important roles in a variety
of cells, RBP-J has been shown to be a common target for
viruses, particularly gammaherpesviruses, which scrounge the
Notch signaling pathway. Examples are KSHV RTA and
LANA (36), murine gammaherpesvirus 68 RTA (51), and
EBV EBNA2 and EBNA3 (21, 30, 54, 59). In all cases, these
viral transcription factors interact with RBP-J and this inter-
action activates target gene expression. Furthermore, the
Notch pathway has also been reported to play a role in the
pathogenesis of adenovirus (19), simian virus 40 (1), and hu-
man papillomavirus (28, 63). Here, we demonstrate that cel-
lular Notch signal transduction not only is partially exchange-
able with RTA in regard to activation of viral lytic gene
expression but also provides a novel expression profile of
KSHV growth and immune deregulatory genes. With all these
activities of Notch signal transduction in mind, further study of
Notch signal transduction should be informative for elucida-
tion of the mechanisms of immune evasion and pathogenesis
associated with KSHV latency.
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